2016
DOI: 10.20996/1819-6446-2016-12-6-703-710
|View full text |Cite
|
Sign up to set email alerts
|

Efficiency of Influenza Vaccination in Patients With Circulatory System Diseases Under Dispensary Observation in Outpatient Clinics: Prospective Follow-Up Monitoring Data

Abstract: Цель. Определить эффективность вакцинации против гриппа у пациентов с болезнями системы кровообращения (БСК), находящихся под диспансерным наблюдением в поликлинике, по данным трехлетнего проспективного наблюдения. Материал и методы. Проведено исследование эффективности вакцинопрофилактики гриппа у лиц с БСК, находящихся под диспансерным наблюдением в 2 поликлиниках г. Иваново и в 2 поликлиниках г. Саратова по данным трехлетнего проспективного контроля. Включено в ис-следование 817 человек, из них согласившихс… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0
2

Year Published

2018
2018
2022
2022

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 14 publications
(7 citation statements)
references
References 20 publications
0
5
0
2
Order By: Relevance
“…pregnant women (31)(32)(33)(34)(35)(36)(37)(38), elderly people aged 60 and over with cardiovascular system diseases (39,40), children and adults with asthma and other chronic obstructive respiratory tract diseases (41)(42)(43)(44), that showed high immunogenicity and good tolerance in all participants from risk groups who are subject to vaccination as part of the Russian national immunization program. Even in patients ≥60 years with diseases of cardiovascular system the level of seroconversion was 49.5-68.5%, GMR was 2.8-5.7, and seroprotection was 83.7-84.8%.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…pregnant women (31)(32)(33)(34)(35)(36)(37)(38), elderly people aged 60 and over with cardiovascular system diseases (39,40), children and adults with asthma and other chronic obstructive respiratory tract diseases (41)(42)(43)(44), that showed high immunogenicity and good tolerance in all participants from risk groups who are subject to vaccination as part of the Russian national immunization program. Even in patients ≥60 years with diseases of cardiovascular system the level of seroconversion was 49.5-68.5%, GMR was 2.8-5.7, and seroprotection was 83.7-84.8%.…”
Section: Discussionmentioning
confidence: 99%
“…Numerous post-registration studies conducted in 2009–2019 were devoted to assessing the safety, immunogenicity, prophylactic and clinical efficacy of the trivalent polymer subunit vaccine against influenza in different risk groups, such as: pregnant women ( 31 – 38 ), elderly people aged 60 and over with cardiovascular system diseases ( 39 , 40 ), children and adults with asthma and other chronic obstructive respiratory tract diseases ( 41 – 44 ), that showed high immunogenicity and good tolerance in all participants from risk groups who are subject to vaccination as part of the Russian national immunization program. Even in patients ≥60 years with diseases of cardiovascular system the level of seroconversion was 49.5–68.5%, GMR was 2.8–5.7, and seroprotection was 83.7–84.8%.…”
Section: Discussionmentioning
confidence: 99%
“…В работе A. Ciszewski [45] было показано, что вакцинация улучшила прогноз пациентов с ишемической болезнью сердца; в нашем центре также проводилась оценка эффективности вакцинации против гриппа у больных с ССЗ, наблюдавшихся в двух поликлиниках городов Саратов и Иваново. Оценка данных трехлетнего проспективного наблюдения показала, что у вакцинированных пациентов отмечалось уменьшение количества случаев ухудшения клинического течения ССЗ, в том числе, развитие инфаркта миокарда, мозгового инсульта и фатальных осложнений [46]. В исследовании J.A.…”
Section: основные закономерности сезонной сердечно-сосудистой смертностиunclassified
“…Today Grippol vaccines are approved and especially recommended for vaccination of cohorts that previously were considered to be not vaccinated (patients with allergic conditions, subjects with chromic somatic diseases, individuals with different immune deficiencies), and children from 6 months of age, and pregnant women. These recommendations were made based on relevant clinical trials results followed by many years practical mass vaccine application experience [66,67].…”
Section: Vaccination Against Influenza: the Prospect Of Using Adjuvantsmentioning
confidence: 99%